Centella for chronic skin inflammation: distinguishing between suppression and resolution

The distinction between suppressing inflammation and resolving its cause

Anti-inflammatory actives like centella asiatica reduce the visible manifestations of inflammation — redness, swelling, sensitivity — by inhibiting the inflammatory cascade at the NF-κB or prostaglandin pathway level. This is genuinely beneficial for reducing visible discomfort and the long-term inflammatory damage that chronic skin inflammation accumulates. However, suppressing the inflammatory signal does not resolve the underlying cause that triggered it — if the cause persists (a harmful product ingredient, a compromised barrier that is repeatedly stressed, a developing allergy, or chronic UV exposure), centella manages the symptom without addressing the source. The risk of centella as a long-term management tool is that it can mask an ongoing problem that should be identified and resolved rather than continually suppressed.

Common causes of chronic skin inflammation that centella alone cannot resolve

Several common causes of persistent skin redness and sensitivity require intervention beyond centella anti-inflammatory support. Fragrance and preservative contact sensitisation: if the skin has developed a type IV hypersensitivity reaction to a specific ingredient (fragrances, some preservatives, lanolin), centella applied in a product that also contains the sensitiser will partially suppress the reaction without resolving it. Barrier disruption from a product still in use: if the routine contains a harsh surfactant, alcohol-heavy toner or over-concentrated active that is consistently disrupting the barrier, centella cannot restore barrier integrity faster than the continued disruption damages it. Rosacea as a medical condition: centella can manage rosacea flares but does not change the underlying vascular and neurovascular dysregulation that drives the condition.

When centella is the correct long-term management tool

For some skin conditions, ongoing centella management is the correct long-term approach rather than a temporary measure pending resolution. Rosacea in remission — after the immediate triggers (sunlight, alcohol, temperature extremes) have been identified and managed — benefits from ongoing centella support that reduces the baseline inflammatory tone of the skin and modulates the vascular responses that produce flushing and erythema. Chronically sensitive skin that has been assessed by a dermatologist and found to not have any addressable underlying cause (no identifiable allergens, no active barrier disruption, no inflammatory skin disease) benefits from centella as an appropriate long-term support for the elevated baseline reactivity. In these cases, centella is not masking a resolvable problem but managing an irreducible minimum of reactive skin tendency.

Combining centella cream with centella serum for multi-depth anti-inflammatory delivery

A centella serum applied at the treatment step delivers madecassoside and asiaticoside to the upper dermis via the serum's penetration characteristics — where the NF-κB inhibition occurs in the keratinocytes and fibroblasts of the dermis. A centella cream applied over it provides additional surface-level anti-inflammatory compounds in the more occlusive cream base, maintaining inflammatory suppression at the barrier level through the day or night. The combination is appropriate for actively inflamed skin during recovery phases — more comprehensive anti-inflammatory coverage than either format alone, with the serum providing depth of delivery and the cream providing duration of surface action.

Transitioning from centella management to a more complete active routine

When centella has successfully suppressed inflammation and the skin has been stable for four to six weeks, the transition to a more complete active routine should be gradual and diagnostic. Introduce one active at a time, with two weeks between each new introduction, to identify which actives the newly stable skin tolerates and which trigger sensitivity. The centella products remain in the routine throughout the transition as a safety net — if a new active triggers a return of sensitivity, the centella support that is already in place limits the severity of the response while the new active is discontinued. This systematic approach prevents the common failure mode of rushing too quickly to a complex routine after stabilisation and recreating the sensitivity from which the recovery phase was needed.